We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEFIE.L Regulatory News (EFIE)

  • There is currently no data for EFIE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Statement re : Fund Closure

28 Mar 2023 16:55

RNS Number : 5222U
IVZ Goldman Sachs EFI Eur UCITS
28 March 2023
 

http://www.rns-pdf.londonstockexchange.com/rns/5222U_1-2023-3-28.pdf

 

 

Invesco Markets plc

Ground Floor, 2 Cumberland Place, Fenian Street, Dublin 2, Ireland

Telephone +353 1 439 8000

www.invesco.com

IMPORTANT: This document is important and requires your immediate attention. If you are in any doubt as to the action you should take you should seek advice from your stockbroker, bank manager, solicitor, accountant or other independent financial adviser.

 

If you have sold or transferred all of your shares in the Fund (as defined below), please pass this document at once to the purchaser or transferee or to the stockbroker, bank or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee as soon as possible.

 

Capitalised terms used herein shall bear the same meaning as capitalised terms used in the Prospectus dated 30 November 2022. Copies of the Prospectus are available upon request during normal business hours from the registered office of the Company or from the local representative of the Company in each jurisdiction in which the sub-funds of the Company are registered for public distribution.

 

In accordance with the current policy of the Central Bank, this document has not been reviewed by the Central Bank.

 

 

 

 

28 March 2023

 

Invesco Markets plc (the "Company")

 

Fund

ISIN

Invesco Goldman Sachs Equity Factor Index Europe UCITS ETF Acc

IE00BMW3NY56

 

(the "Fund")

 

Dear Shareholder,

 

We are writing to you as a Shareholder in the Fund to inform you that the board of directors (the "Board") has, with regret, determined that, pursuant to Clause 10 Appendix II of the Memorandum & Articles of Association of the Company (the "M&A"), it is in the best interests of the Shareholders to terminate the Fund with effect from 10 May 2023 (the "Termination Date").

 

The decision of the Board to terminate the Fund is based on the advice of the promoter and investment manager that the continued existence and operation of the Fund is not economically viable.

 

Therefore, in accordance with the above provisions of the M&A and the Prospectus, the Board hereby gives notice of our intention:

i) cancel the listing of the Fund and the right of the Fund to be traded on any relevant stock exchanges with effect from close of business on 28 April 2023;

ii) terminate the Fund with effect from 3 May 2023; and

iii) to proceed with the compulsory repurchase of all outstanding shares of the Fund.

 

 

PROPOSED TIMETABLE

 

Key Dates

Event

28 April 2023 (Friday)

Final Exchange Trading Date

2 May 2023 (Tuesday)

Final Dealing Date (Voluntary Create/Redeem)

3 May 2023 (Wednesday)

Mandatory Redemption Trade Date (and Termination Date)

10 May 2023 (Wednesday)

Redemption Settlement Date

 

 

ADDITIONAL INFORMATION

 

Requests for repurchase or subscription for Shares in the Fund may be made in the usual manner in accordance with the Prospectus and supplements for the Fund (the "Supplement") until 2 May 2023.

 

The following terms and conditions of such compulsory repurchase shall apply as of the Termination Date:

 

1. the Fund shall be terminated and the repurchase price for each Class of Shares of the Fund will be determined by reference to the Net Asset Value of the respective Class of Shares of the Fund as of the Termination Date. The costs in relation to the termination will be borne by the Manager;

 

2. no repurchase charge will be applied;

 

3. the repurchase proceeds will be paid in the relevant Share Class currency;

 

4. the payment of the repurchase proceeds resulting from the compulsory repurchase will take place on or around 10 May 2023; and

 

5. following the payment of the repurchase proceeds in respect of the Fund, application will be made to the Central Bank of Ireland for the withdrawal of approval of the Fund.

 

Shareholders who subscribe or repurchase Shares in the Fund on the primary market are entitled to repurchase their Shares in the Fund in accordance with the Prospectus. Please note that the Company does not charge any repurchase fee for the sale of Shares in the secondary market. Orders to sell Shares through a stock exchange can be placed via an authorised intermediary or stockbroker. However, Shareholders should note that orders in the secondary market may incur costs over which the Company has no control and to which the above disapplication of the repurchase charge does not apply.

 

Shareholders may obtain the Prospectus, a copy of the Supplements, the key investor information and key information documents, the latest annual and semi-annual reports and copies of the M&A free of charge from the registered office of the Manager or the local representatives in the countries where the Company is registered and in Switzerland at BNP Paribas Securities Services, Paris, succursale de Zurich, Selnaustrasse 16, 8002 Zurich which is the Swiss representative and paying agent, as well as from the German information agent Marcard, Stein & Co AG, Ballindamm 36, 20095 Hamburg, Germany and where applicable on the website of the Company - www.etf.invesco.com. Shareholders should consult their own professional advisers as to the specific tax implications of the termination under the laws of the countries of their nationality, residence, domicile or incorporation.

 

If you have any queries arising from this notice, please call Invesco on +353 1 439 8000 or contact us at invest@invesco.com.

 

Yours sincerely

 

 

_________________

For and on behalf of

Invesco Markets plc

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRSEFFIAEDSEID
Date   Source Headline
28th Apr 202310:21 amRNSNet Asset Value(s)
27th Apr 202311:49 amRNSNet Asset Value(s)
26th Apr 202310:54 amRNSNet Asset Value(s)
25th Apr 202310:35 amRNSNet Asset Value(s)
24th Apr 202310:08 amRNSNet Asset Value(s)
21st Apr 202310:10 amRNSNet Asset Value(s)
20th Apr 202310:12 amRNSNet Asset Value(s)
19th Apr 20239:56 amRNSNet Asset Value(s)
18th Apr 20239:37 amRNSNet Asset Value(s)
17th Apr 202310:17 amRNSNet Asset Value(s)
14th Apr 20239:03 amRNSNet Asset Value(s)
13th Apr 202310:05 amRNSNet Asset Value(s)
12th Apr 202310:28 amRNSNet Asset Value(s)
11th Apr 202310:29 amRNSNet Asset Value(s)
6th Apr 20239:20 amRNSNet Asset Value(s)
5th Apr 202311:04 amRNSNet Asset Value(s)
4th Apr 20239:12 amRNSNet Asset Value(s)
3rd Apr 202310:15 amRNSNet Asset Value(s)
31st Mar 202311:33 amRNSNet Asset Value(s)
30th Mar 202310:02 amRNSNet Asset Value(s)
29th Mar 20233:02 pmRNSNet Asset Value(s)
28th Mar 20234:55 pmRNSStatement re : Fund Closure
28th Mar 202310:35 amRNSNet Asset Value(s)
27th Mar 20239:58 amRNSNet Asset Value(s)
24th Mar 202310:15 amRNSNet Asset Value(s)
23rd Mar 20239:30 amRNSNet Asset Value(s)
22nd Mar 20239:29 amRNSNet Asset Value(s)
21st Mar 20239:29 amRNSNet Asset Value(s)
20th Mar 202310:04 amRNSNet Asset Value(s)
17th Mar 20239:58 amRNSNet Asset Value(s)
16th Mar 20231:10 pmRNSNet Asset Value(s)
15th Mar 20231:45 pmRNSNet Asset Value(s)
14th Mar 202312:29 pmRNSNet Asset Value(s)
13th Mar 202311:28 amRNSNet Asset Value(s)
10th Mar 202310:09 amRNSNet Asset Value(s)
9th Mar 202310:01 amRNSNet Asset Value(s)
8th Mar 202310:03 amRNSNet Asset Value(s)
7th Mar 202310:14 amRNSNet Asset Value(s)
6th Mar 202311:53 amRNSNet Asset Value(s)
3rd Mar 20231:50 pmRNSNet Asset Value(s)
2nd Mar 20239:54 amRNSNet Asset Value(s)
1st Mar 202310:45 amRNSNet Asset Value(s)
28th Feb 202310:08 amRNSNet Asset Value(s)
27th Feb 20239:54 amRNSNet Asset Value(s)
24th Feb 20239:25 amRNSNet Asset Value(s)
23rd Feb 20239:41 amRNSNet Asset Value(s)
22nd Feb 20239:38 amRNSNet Asset Value(s)
21st Feb 20238:18 amRNSNet Asset Value(s)
20th Feb 20239:32 amRNSNet Asset Value(s)
17th Feb 20239:33 amRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.